|
Latest News |
|
|
TaiGen Biotechnology obtains the worldwide rights for Nemonoxacin
2011/12/06
More»
TaiGen Amends Global License Agreement with Warner Chilcott plc for Development and Commercialization of Nemonoxacin -- a New Generation Quinolone Antibiotic
2010/10/14
More»
TaiGen Announces Nemonoxacin (TG-873870) Once-A-Day Oral Dosing in Diabetic Foot Infection Met Primary Endpoints
2010/03/12
More»
TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting
2009/12/07
More»
Excellent Stem Cell Mobilization and Safety Profile for TG-0054
2009/09/28
More»
TaiGen Biotechnology Secures 37 Million USD in Series C Round Financing
2009/01/20
More» |
|
TaiGen Biotechnology Co., Ltd.
7F, 138 Shin Ming Rd. Neihu Dist.,
Taipei, Taiwan 114 R.O.C.
Tel: 886-2-81777072
886-2-27901861
Fax: 886-2-27963606
service@taigenbiotech.com.tw
TaiGen Biopharmaceuticals Co. (Beijing), Ltd.
Suite 2209, A Tower, FULL LINK Building
No. 18 Chaoyangmenwaidajie,
Beijing 100020, China
Tel: 86-10-65885166
Fax: 86-10-65885167
For investor relations, please contact:
PJ (Joe) Hsueh, Vice President of Operations
Tel. 886-2-81777072 ext 1704
886-933-917-804
pjhsueh@taigenbiotech.com.tw
For business development opportunities, please contact:
Dr. Peter W. Tsao, VP Global Business Development
Tel: 886-2-2790-1861
ptsao@taigenbiotech.com.tw
Location maps:
Taipei Office
View Larger Map
Beijing Office
View Larger Map
|
|
|
